Other News

Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21

Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances […]

mSToPS Clinical Trial Demonstrates Zio by iRhythm Significantly Improves Health Outcomes for At-Risk Patient Populations

Data published in PLOS One shows continuous monitoring leads to earlier diagnosis and prevents adverse cardiac events, furthering the case for cardiac screening SAN FRANCISCO, Oct. 05, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announced the results of […]

PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial), the pivotal Phase 3 trial designed to study reversal of the antiplatelet effects of […]

ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the Treatment of Hypertension in Europe

Treatment Supported by Evidence from Multiple Studies and Renal Denervation Position Paper from the European Society of Hypertension PALO ALTO, Calif. & FRANKFURT, Germany–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the company’s Paradise™ Ultrasound Renal Denervation System (the “Paradise™ […]

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary […]

GE Healthcare Receives FDA Approval for Change in Contraindications in Prescribing Information for OptisonTM

MARLBOROUGH, Mass.–(BUSINESS WIRE)–GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood products’ from the contraindications in its prescribing information for its product OptisonTM (Perflutren Protein-Type A Microspheres Injectable Suspension, USP). Optison is an ultrasound enhancing agent […]

VUNO Signs Another Deal with Samsung Electronics to Incorporate AI-assisted Solutions into Samsung’s Premium Ceiling Type Digital Radiography System

SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ — South Korean artificial intelligence (AI) developer, VUNO Inc., announced today that the company closed a deal with global medical device manufacturer, Samsung Electronics Co., Ltd., to embed VUNO’s artificial intelligence-driven chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™ into Samsung’s GC85A premium ceiling type digital […]

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company’s common stock, at a purchase price of $3.25 per share. […]

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon

Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The data […]